



Vascular Anomalies Canada
Anomalies Vasculaires Canada


Apelisib Survey Summary

October 2022

Survey Details

- Distributed: 88 members
- Responses: 31
 - 35% response rate
- 29 patients from various sites are currently receiving Alpelisib
- 12 were identified to be treated with Sirolimus prior to Alpelisib


Response by Specialty



- Dermatologist
- Geneticist
- Adult Hemato-Oncologist
- Pediatric Hemato-Oncologist
- Internal Medicine
- Nurse
- Obstetrician/Gynecologist
- Otolaryngology
- Pathology
- Pediatrician
- Radiologist
- Researcher
- Surgeon
- Social Worker
- Physiotherapist
- Unknown


Are you an Alpelisib prescriber ?

31 responses




- No
- Yes

If you are an Alpelisib prescriber, do you prescribe Alpelisib for
7 responses



What is your usual process before initiating Alpelisib ?


13 responses



- I make the decision on my own based on available knowledge
- We discuss in a multidisciplinary VA team
- I consult colleagues from other centers
- I consult colleagues from my center
- We have not been using this medication
- All of the above

How do you access Alpelisib?


10 responses



- Managed access program from Novartis (MAP)
- Provincial process
- Private insurance
- EPIK-P2 study (study of Novartis)
- EPIK P2 and MAP

Why are patients changed from Sirolimus to Alpelisib?

8 responses



- No response to sirolimus
- Partial response to sirolimus
- Adverse effects on sirolimus
- no current patients on this medication
- Not Applicable
- Alpelisib superior for VM and FIL
- Facial infiltrating lipomatosis... not known to respond to sirolimus as well as alpelisib
- Partial or no response to sirolimus